Cargando…
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
Since the discovery of targeted therapy with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been introduced as the first-line treatment for non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations. Co...
Autores principales: | Wang, Li, Wang, Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709813/ https://www.ncbi.nlm.nih.gov/pubmed/33200229 http://dx.doi.org/10.3892/or.2020.7851 |
Ejemplares similares
-
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019) -
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019) -
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023) -
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
por: Zhou, F., et al.
Publicado: (2023) -
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
por: Ou, Sai-Hong Ignatius
Publicado: (2011)